Cita APA

Verlingue, L., Prenen, H., Guerra Alia, E. M., Tosi, D., ITALIANO, A., Perets, R., & OAKNIN, A. (2024). Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

Citación estilo Chicago

Verlingue, Loic, Hans Prenen, Eva Maria Guerra Alia, Diego Tosi, ANTOINE ITALIANO, Ruth Perets, y ANA OAKNIN. Phase 2 Study of the Antitumour Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined With Atezolizumab in Patients With Recurrent And/or Metastatic Cervical Squamous Cell Carcinoma. 2024.

Cita MLA

Verlingue, Loic, et al. Phase 2 Study of the Antitumour Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined With Atezolizumab in Patients With Recurrent And/or Metastatic Cervical Squamous Cell Carcinoma. 2024.